ABHD7 Inhibitors

The class of ABHD7 inhibitors comprises a range of compounds that target the enzyme ABHD7, directly or indirectly influencing its hydrolase activity. One such inhibitor, WWL70, directly modulates ABHD7, disrupting endocannabinoid metabolism and signaling pathways associated with lipid homeostasis and inflammation. The inhibition of ABHD7 by WWL70 provides a specific means to impact cellular processes linked to the enzyme's activity. KT185, another selective ABHD7 inhibitor, directly influences ABHD7 hydrolase activity, affecting endocannabinoid metabolism and signaling pathways related to lipid homeostasis and inflammation. The direct modulation of ABHD7 by KT185 offers a targeted approach to influence cellular processes associated with the enzyme's function. Notably, KT5720, a PKA inhibitor, indirectly influences ABHD7 by modulating the cAMP/PKA signaling pathway. As ABHD7 activity is regulated by cAMP-dependent phosphorylation, KT5720's impact on PKA can lead to altered ABHD7 function, affecting endocannabinoid metabolism and related cellular processes. MAFP, an irreversible serine hydrolase inhibitor, indirectly affects ABHD7 by inhibiting its hydrolase activity. This inhibition alters endocannabinoid metabolism and signaling, influencing cellular processes associated with lipid homeostasis and inflammation.

JZP-430, an ABHD7 inhibitor, directly targets the enzyme's hydrolase activity, disrupting endocannabinoid metabolism and signaling pathways. The direct modulation of ABHD7 by JZP-430 provides a specific means to influence cellular processes associated with the enzyme's activity. LY2183240, an mTOR inhibitor, indirectly influences ABHD7 by modulating the mTOR signaling pathway. As ABHD7 activity is connected to mTOR-regulated processes, LY2183240's impact on mTOR can lead to altered ABHD7 function, affecting endocannabinoid metabolism and related cellular processes. URB602, an ABHD6 and ABHD12 inhibitor, indirectly impacts ABHD7 by modulating endocannabinoid levels. By inhibiting ABHD6, URB602 elevates anandamide levels, affecting signaling pathways associated with lipid metabolism and inflammation. In summary, the diverse group of ABHD7 inhibitors offers both direct and indirect means to modulate the enzyme's activity, impacting endocannabinoid metabolism and signaling pathways associated with lipid homeostasis and inflammation. The specific mechanisms of action of these inhibitors provide valuable tools for investigating the intricate regulatory networks governing cellular processes and their potential connections to ABHD7.